Bone Hormones: Survival of the glycosylated
Osteocalcin is a bone matrix protein that acts like a hormone when it reaches the blood, and has different effects in mice and humans.
- Veterans Affairs Medical Center and the Department of Pathology, University of Pittsburgh, United States
- Department of Cell Biology and Physiology, Washington University School of Medicine, United States
Bone tissue is constantly being created and replaced in a process called remodeling. This involves cells called osteoblasts making bone and others cells called osteoclasts taking up the various minerals and proteins released from the degraded bone and discharging them into the blood (Figure 1). Osteocalcin is a protein found in bone tissue and is abundantly present in amounts equimolar to collagen – the structural protein of bone. Once absorbed by osteoclasts, osteocalcin displays variable carboxylation (the adding of a carboxyl acid group to the protein sequence) and is cleaved at various sites during its release.
Figure 1
How osteocalcin is synthesized and released into the blood.
The protein osteocalcin (red dots) resides in the bone matrix with collagen (green) and other matrix proteins integrated into mineralized bone. Bone tissue is broken down by cells called osteoclasts (shape outlined in blue), and left-over proteins – including osteocalcin – are partially degraded and discharged into the blood.
The osteocalcin molecules that reach the blood are a complex family of distinctive small peptides, most of which are less than 1000 kDa in weight (Blair et al., 1986). The family of discharged peptides include mixtures of intact or cleaved osteocalcin (Ivaska et al., 2004) and partially uncarboxylated protein (Poser and Price, 1979; Cairns and Price, 1994). These molecules behave like hormones, traveling to other organs in the body – such as the pancreas and liver – where they help to regulate metabolic processes (Tsuka et al., 2015).
It is widely posited that bone acts as endocrine organ that contributes to metabolic regulation (Dirckx et al., 2019). For example, knocking out the gene for osteocalcin in mice has been shown to impair glucose tolerance, to lead to increase bone formation, and to reduce testosterone production and muscle mass. However, these metabolic changes are variable and do not occur in all mouse models (Komori, 2020).
The G-protein receptor that osteocalcin binds to can also interact with numerous other ligands, such as calcium and steroids, which may be responsible for these differing observations (Pi et al., 2005). Furthermore, other hormones that bind to G-protein receptors, such as follicle stimulating hormone, have been found to activate receptors not on their target organ, and cause additional, unexpected effects (Sun et al., 2006). Together, this demonstrates the challenges associated with studying the function of osteocalcin, and why there is still a great deal to learn about the various roles of osteocalcin in mammals, including humans.
To coordinate metabolism in diverse tissues, the modified osteocalcin needs to be maintained at high levels in the blood and not be immediately removed by the kidney’s filtration system and discharged in the urine. Now, in eLife, Mathieu Ferron and co-workers from the Montreal Clinical Research Institute, the University of Montreal, the University of Copenhagen and McGill University – including Omar Al Rifai as first author – report how osteocalcin in mice is able to survive for longer in the blood than human osteocalcin (Al Rifai et al., 2020).
The team found that mouse osteocalcin undergoes an additional modification, which attaches a small sugar group called an O-glycan to a serine residue in the protein. Al Rifai et al. discovered that this sugar group prevented osteocalcin from being degraded by enzymes in the blood. Human osteocalcin was found to have a tyrosine residue at this site: however, when this was replaced with a serine residue, O-glycan groups were able to bind to the hormone and make it more stable, causing it to persist for longer in the blood. This difference in stability is likely what causes mice to have 5–10 times more osteocalcin in their blood than humans.
Much of what is known about the influence of osteocalcin on metabolism has come from experiments on mice. However, in addition to having different levels of osteocalcin, the molecular biology of this hormone also differs between humans and mice. In rodents, osteocalcin is coded by a cluster of three genes, two of which are expressed in osteoblasts (Moriishi et al., 2020), whereas human osteocalcin is coded by a single gene (Celeste et al., 1986).
Further work is needed to address other aspects of how osteocalcin is processed and regulated in humans. Previous studies suggest that levels of human osteocalcin are also regulated by the rate at which osteoclasts break down the bone’s tissue, and inhibiting this process has been found to reduce the amounts of osteocalcin in the blood by 30% (Zhou et al., 2020). However, the degradation of bone might not be the sole source of osteocalcin in humans (Figure 1), and some of our experiments suggest that when levels of osteocalcin are low, cells other than osteoblasts may also release moderate amounts of decarboxylated osteocalcin into the blood; but this remains to be established. This suggestion is supported by the fact that while decarboxylation in osteoclasts has not been fully studied, the process has been shown to be acid driven in vitro, and therefore unlikely to occur in osteoclasts (Poser and Price, 1979).
The findings of Al Rifai et al. demonstrate the challenges involved in extrapolating results about hormones and metabolism from mice to humans. Further work is still needed to fully understand the role of osteocalcin in humans, and to gain a clearer understanding of how levels of this hormone are regulated.
References
-
Isolated osteoclasts resorb the organic and inorganic components of boneThe Journal of Cell Biology 102:1164–1172.https://doi.org/10.1083/jcb.102.4.1164
-
Direct demonstration that the vitamin K-dependent bone gla protein is incompletely γ-carboxylated in humansJournal of Bone and Mineral Research 9:1989–1997.https://doi.org/10.1002/jbmr.5650091220
-
The role of osteoblasts in energy homeostasisNature Reviews Endocrinology 15:651–665.https://doi.org/10.1038/s41574-019-0246-y
-
Release of intact and fragmented osteocalcin molecules from bone matrix during bone resorption in vitroJournal of Biological Chemistry 279:18361–18369.https://doi.org/10.1074/jbc.M314324200
-
Functions of osteocalcin in bone, pancreas, testis, and muscleInternational Journal of Molecular Sciences 21:7513.https://doi.org/10.3390/ijms21207513
-
Identification of a novel extracellular cation-sensing G-protein-coupled receptorJournal of Biological Chemistry 280:40201–40209.https://doi.org/10.1074/jbc.M505186200
-
A method for decarboxylation of gamma-carboxyglutamic acid in proteinsJournal of Biological Chemistry 254:431–436.https://doi.org/10.1016/S0021-9258(17)37935-8
-
Promotion of insulin-induced glucose uptake in C2C12 myotubes by osteocalcinBiochemical and Biophysical Research Communications 459:437–442.https://doi.org/10.1016/j.bbrc.2015.02.123
Article and author information
Author details
Paul H Schlesinger
Acknowledgements
We acknowledge support from the Department of Veterans Affairs (Grant BX002490) and NIH (Grant AR-065407).
Publication history
- Version of Record published: January 22, 2021 (version 1)
Copyright
© 2021, Blair and Schlesinger
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 673
- views
-
- 64
- downloads
-
- 1
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Bone Hormones: Survival of the glycosylated
eLife 10:e65719.
https://doi.org/10.7554/eLife.65719
Further reading
-
- Biochemistry and Chemical Biology
Truncation of the protein-protein interaction SH3 domain of the membrane remodeling Bridging Integrator 1 (BIN1, Amphiphysin 2) protein leads to centronuclear myopathy. Here, we assessed the impact of a set of naturally observed, previously uncharacterized BIN1 SH3 domain variants using conventional in vitro and cell-based assays monitoring the BIN1 interaction with dynamin 2 (DNM2) and identified potentially harmful ones that can be also tentatively connected to neuromuscular disorders. However, SH3 domains are typically promiscuous and it is expected that other, so far unknown partners of BIN1 exist besides DNM2, that also participate in the development of centronuclear myopathy. In order to shed light on these other relevant interaction partners and to get a holistic picture of the pathomechanism behind BIN1 SH3 domain variants, we used affinity interactomics. We identified hundreds of new BIN1 interaction partners proteome-wide, among which many appear to participate in cell division, suggesting a critical role of BIN1 in the regulation of mitosis. Finally, we show that the identified BIN1 mutations indeed cause proteome-wide affinity perturbation, signifying the importance of employing unbiased affinity interactomic approaches.
-
- Biochemistry and Chemical Biology
- Chromosomes and Gene Expression
Recent findings indicate that the translation elongation rate influences mRNA stability. One of the factors that has been implicated in this link between mRNA decay and translation speed is the yeast DEAD-box helicase Dhh1p. Here, we demonstrated that the human ortholog of Dhh1p, DDX6, triggers the deadenylation-dependent decay of inefficiently translated mRNAs in human cells. DDX6 interacts with the ribosome through the Phe-Asp-Phe (FDF) motif in its RecA2 domain. Furthermore, RecA2-mediated interactions and ATPase activity are both required for DDX6 to destabilize inefficiently translated mRNAs. Using ribosome profiling and RNA sequencing, we identified two classes of endogenous mRNAs that are regulated in a DDX6-dependent manner. The identified targets are either translationally regulated or regulated at the steady-state-level and either exhibit signatures of poor overall translation or of locally reduced ribosome translocation rates. Transferring the identified sequence stretches into a reporter mRNA caused translation- and DDX6-dependent degradation of the reporter mRNA. In summary, these results identify DDX6 as a crucial regulator of mRNA translation and decay triggered by slow ribosome movement and provide insights into the mechanism by which DDX6 destabilizes inefficiently translated mRNAs.
